Enlivex Therapeutics Ltd. 1BT.F Stock
Enlivex Therapeutics Ltd. Price Chart
Enlivex Therapeutics Ltd. 1BT.F Financial and Trading Overview
| Enlivex Therapeutics Ltd. stock price | 1.74 EUR |
| Previous Close | 1.59 EUR |
| Open | 1.58 EUR |
| Bid | 1.57 EUR x 500000 |
| Ask | 1.63 EUR x 500000 |
| Day's Range | 1.58 - 1.58 EUR |
| 52 Week Range | 1.2 - 4.57 EUR |
| Volume | 100 EUR |
| Avg. Volume | 0 EUR |
| Market Cap | 30.49M EUR |
| Beta (5Y Monthly) | 0.738 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.37 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
1BT.F Valuation Measures
| Enterprise Value | 3.41M EUR |
| Trailing P/E | N/A |
| Forward P/E | -1.025974 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.7577938 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.131 |
Trading Information
Enlivex Therapeutics Ltd. Stock Price History
| Beta (5Y Monthly) | 0.738 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 4.57 EUR |
| 52 Week Low | 1.2 EUR |
| 50-Day Moving Average | 1.48 EUR |
| 200-Day Moving Average | 2.42 EUR |
1BT.F Share Statistics
| Avg. Volume (3 month) | 0 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 18.6M |
| Float | 14.51M |
| Short Ratio | N/A |
| % Held by Insiders | 11.82% |
| % Held by Institutions | 9.78% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:8 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | September 30, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -28.17% |
| Return on Equity (ttm) | -53.23% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -26049000 EUR |
| Net Income Avi to Common (ttm) | -27162000 EUR |
| Diluted EPS (ttm) | -1.35 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 30.5M EUR |
| Total Cash Per Share (mrq) | 1.64 EUR |
| Total Debt (mrq) | 4.52M EUR |
| Total Debt/Equity (mrq) | 11.65 EUR |
| Current Ratio (mrq) | 7.338 |
| Book Value Per Share (mrq) | 2.085 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -23064000 EUR |
| Levered Free Cash Flow (ttm) | -16470625 EUR |
Profile of Enlivex Therapeutics Ltd.
| Country | Germany |
| State | N/A |
| City | Ness Ziona |
| Address | 14 Einstein Street |
| ZIP | 7403618 |
| Phone | 972 8 662 3301 |
| Website | https://www.enlivex.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Q&A For Enlivex Therapeutics Ltd. Stock
What is a current 1BT.F stock price?
Enlivex Therapeutics Ltd. 1BT.F stock price today per share is 1.74 EUR.
How to purchase Enlivex Therapeutics Ltd. stock?
You can buy 1BT.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Enlivex Therapeutics Ltd.?
The stock symbol or ticker of Enlivex Therapeutics Ltd. is 1BT.F.
Which industry does the Enlivex Therapeutics Ltd. company belong to?
The Enlivex Therapeutics Ltd. industry is Biotechnology.
How many shares does Enlivex Therapeutics Ltd. have in circulation?
The max supply of Enlivex Therapeutics Ltd. shares is 18.6M.
What is Enlivex Therapeutics Ltd. Price to Earnings Ratio (PE Ratio)?
Enlivex Therapeutics Ltd. PE Ratio is now.
What was Enlivex Therapeutics Ltd. earnings per share over the trailing 12 months (TTM)?
Enlivex Therapeutics Ltd. EPS is -1.37 EUR over the trailing 12 months.
Which sector does the Enlivex Therapeutics Ltd. company belong to?
The Enlivex Therapeutics Ltd. sector is Healthcare.